Abstract
Background Chronic kidney disease (CKD) is a frequent comorbidity in heart failure (HF) patients, affecting prognosis and mortality. This study investigates the relationship between kidney function and adverse kidney events preceding death in HF patients.
Methods We analyzed registry data of HF patients who died between 2014 and 2021, with at least one year of HF diagnosis. Adverse kidney events, including acute kidney injury (AKI) and end- stage kidney disease (ESKD), were assessed. Patients were grouped by estimated glomerular filtration rate (eGFR) one year before death: eGFR≥60, eGFR 30-59, and eGFR<30.
Results Among 36,435 HF patients who died, 37% had eGFR≥60, 46% had eGFR 30-59, and 17% had eGFR<30 one year before death. Median age was 81 years, and 61.2% were men. Adverse kidney events occurred in 13.1% of patients. AKI was inversely related to kidney function, affecting 6.5% (95% confidence interval 6.1-6.9) of those with eGFR≥60, 7.0% (6.6.-7.4) with eGFR 30-59, and 21.9% (20.9-22.9) with eGFR<30. ESKD occurred in 0.7%(0.6-0.9), 2.6% (2.4-2.8), and 35.5% (34.3-36.7) of patients in the respective eGFR categories. In the last three months before death, kidney function notably declined, with increased chronic kidney replacement therapy. Factors associated with higher adverse kidney events included younger age, male sex, in-hospital death, and greater frailty.
Conclusions In HF patients, AKI and ESKD are common in the last year of life, particularly in those with lower baseline eGFR, with kidney decline accelerating in the final months.
Competing Interest Statement
Dr. Elmegaard reports unrestricted hospital grant from Gentofte Hospital, unrestricted grant from Danish Cardiovascular Academy, grant from Novofoundation, and stocks from Novo Nordisk A/S, Cessatech A/S, Bavarian A/S. Dr. Carlson reports lecture honoraria AstraZeneca and board member Danish Society of Nephrology. Dr. Jhund reports speakers' fees from AstraZeneca, Novartis, Alkem Metabolics, ProAdWise Communications, Sun Pharmaceuticals; advisory board fees from AstraZeneca, Boehringer Ingelheim, Novartis; research funding from AstraZeneca, Boehringer Ingelheim, Analog Devices Inc, Roche Diagnostics. PSJ's employer the University of Glasgow has been remunerated for clinical trial work from AstraZeneca, Bayer AG, Novartis and Novo Nordisk. Director GCTP Ltd. Dr. Petrie reports research funding from Boehringer Ingelheim, Roche, SQ Innovations, Astra Zeneca, Novartis, Novo Nordisk, Medtronic, Boston Scientific, Pharmacosmos, consultancy and trial committees Abott, Akero, Applied Therapeutics, Amgen, AnaCardio, Biosensors, Boehringer Ingelheim, Corteria, Novartis, Astra Zeneca, Novo Nordisk, Abbvie, Bayer, Horizon Therapeutics, Foundry, Takeda, Cardiorentis, Pharmacosmos, Siemens, Eli Lilly, Vifor, New Amsterdam, Moderna, Teikoku, LIB Therapeutics, 3R Lifesciences, Reprieve, FIRE 1, Corvia, Regeneron. Dr. McMurray reports grants from British Heart Foundation, National Institute for Health- National Heart Lung, and Blood Institute (NIH-NHLBI), Boehringer Ingelheim, SQ Innovations, Catalyze Group, consulting fees from Alynylam Pharmaceuticals, Amgen, AnaCardio, AstraZeneca, Bayer, Berlin Cures, BMS, Cardurion, Cytokinetics, Ionis Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, River 2 Renal Corp, Novartis, Cytokinetics, Amgen, GSK, Cardurion, Bayer, AstraZeneca, Global Clinical Trial Partners Ltd, honoraria from Abbott, Alkem Metabolics, Astra Zeneca, Blue Ocean Scientific Solutions Ltd., Boehringer Ingelheim, Canadian Medical and Surgical Knowledge, Emcure Pharmaceuticals Ltd., Eris Lifesciences, European Academy of CME, Hikma Pharmaceuticals, Imagica Health, Intas Pharmaceuticals, J.B. Chemicals & Pharmaceuticals Ltd., Lupin Pharmaceuticals, Medscape/Heart.Org., ProAdWise Communications, Radcliffe Cardiology, Sun Pharmaceuticals, The Corpus, Translation Research Group, Translational Medicine Academy, Participation on a Data Safety Monitoring Board or Advisory Board from WIRB-Copernicus Group Clinical Inc. Dr. Køber reports speakers honorarium from Astra Zeneca, Boehringer, Novartis and Novo Nordisk. Dr. Schou reports lecture fees from Novartis, Novo Nordisk, Astra Zeneca, Bohringer and travel grant from Bayer. The remaining authors have nothing to disclose.
Funding Statement
The study was supported by an unrestricted hospital grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Retrospective register-based studies do not need ethical approval in Denmark. The Danish Data Protection Agency has approved the data access.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are derived from Danish administrative registries, which are not publicly available due to legal and privacy restrictions under Danish data protection regulations. Access to these data can only be granted through secure research environments managed by Danish authorities. Researchers may request access by contacting the corresponding author, subject to approval from the relevant data protection agency and in accordance with institutional and ethical guidelines.
